$Bob's and Jbem's Bitchin' Bios

[ash111]

DCTH DD: Delcath receives new FDA approval back in 2015 for "a type of liver cancer that affects bile ducts". it seems(DCTH known as confidentiality Co.) they did some major steps forward since then( beside closed $35 Million Funding Round back in June 2016,"One of the targets is in the Phase 2 and Phase 3 study of its Melphalan/HDS").

http://poststar.com/business/local/delcath-receives-new-fda-approval/article_0d206ce0-cfe0-5fa2-97cc-d7c911d1848d.html

DCTH ($6m cap,P2/P3 Company, 1.5m O/S) mentioned, just recently, as a major key player for Bile Duct Cancer,among big name companies : http://finance.yahoo.com/news/world-bile-duct-cancer-cholangiocarcinoma-150500717.html

based on last 10Q only,cash burn rate was about 5m(for six month).i would say 40m(cash+restricted) should be sufficient for 3 yrs.imo

Many events (Sept/Oct/Nov) makes it more interesting: http://delcath.com/reuters-events-roll/